Ricky

Ricky asked for updates on Tempus AI's foundation model work with AstraZeneca and Pathos, including key milestones, and how the recent Paige acquisition benefits this foundation model development.

Answer

CEO Eric Lefkofsky reported that the foundation model is successfully completing its pre-training phase, showing strong predictive performance against benchmarks. It is now entering a large compute phase, with post-training expected in late 2025/early 2026, and first model versions anticipated in Q1. He highlighted Tempus AI's significant investment in GPU capacity and its tech-company-like approach to AI. The Paige acquisition is beneficial as Paige.AI had its own foundation model work in digital pathology, and their teams and data are now integrated, adding momentum to Tempus AI's efforts.

Ricky asked for updates on the foundation model work with AstraZeneca and Pathos, including next milestones, and any benefits derived from the Paige acquisition for this work.

Answer

Eric Lefkofsky (CEO, Tempus AI) reported the foundation model is successfully finishing its pre-training phase, entering a large compute phase, with post-training starting late 2025/early 2026, and first model versions expected in Q1 2026. He highlighted strong progress, plans for additional GPU capacity, and the integration of Paige AI's digital pathology foundation model work and team, enhancing momentum.